A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2+1 Dose Series of Either CRM197-Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-Conjugate Haemophilus Influenzae Type b Vaccine
Phase of Trial: Phase III
Latest Information Update: 17 Nov 2015
Price : $35 *
At a glance
- Drugs TAK 816 (Primary) ; Hib vaccine conjugate
- Indications Gram-negative infections; Haemophilus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Novartis
- 22 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 06 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014, as reported by ClinicalTrials.gov record.